Resveratrol suppresses interleukin‐6 expression through activation of sirtuin 1 in hypertrophied H9c2 cardiomyoblasts
- 5 February 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (10) , 6969-6977
Abstract
Inflammatory cytokine, interleukin‐6 (IL‐6), plays an important role in the pathogenesis of cardiac hypertrophy. Recent studies have documented that resveratrol exhibits cardioprotective effects. The present study attempts to explore whether resveratrol suppreses IL‐6 in hypertrophied H9c2 cardiomyoblasts through histone deacetylase, sirtuin 1 (SIRT1). To induce hypertrophy, the cells were incubated with angiotensin II (Ang II). Treatment groups were treated with different doses (1, 10, 25, 50, 75, and 100 μM) of resveratrol (R). Cell viability was measured using 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay. Cell size was determined using crystal violet staining. Gene expression was assessed by real‐time polymerase chain reaction technique. Enzyme‐linked immunosorbent assay was used to measure IL‐6 concentration. The results showed that cell area and ANP messenger RNA (mRNA) levels decreased significantly in R25+Ang, R50+Ang, and R100+Ang groups, as compared with Ang group. Therefore, 10, 20, 30, 40, and 50 μM of resveratrol were used to to evaluate its anti‐inflammatory effects. The results revealed that Ang II upregulated IL‐6 at both mRNA and protein levels (p < .001 vs. normal) and resveratrol (50 μM) decreased IL‐6 mRNA (p < .01) and protein (p < .05) significantly in comparison to Ang group. However, in groups in which the cells were pretreated with SIRT1 inhibitor, EX‐527, the response of resveratrol was partially reversed. Transcription levels of IL‐6 receptor components (gp130 and gp80) did not change significantly among the experimental groups. The current data suggests that resveratrol protects H9c2 cells against Ang II‐induced hypertrophy by suppression of IL‐6 through SIRT1 activation.Keywords
Funding Information
- Shahid Sadoughi University of Medical Sciences
This publication has 33 references indexed in Scilit:
- Resveratrol prevents pathological but not physiological cardiac hypertrophyJournal of Molecular Medicine, 2014
- p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activationCellular Signalling, 2013
- Targeting Cardiovascular Disease With Novel SIRT1 PathwaysFuture Cardiology, 2011
- Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategiesPharmacology & Therapeutics, 2010
- Angiotensin II revisited: new roles in inflammation, immunology and agingEMBO Molecular Medicine, 2010
- Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1–FoxO1 pathwayBiochemical and Biophysical Research Communications, 2009
- Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and AktJournal of Biological Chemistry, 2008
- Anti-Inflammatory Responses of ResveratrolInflammation & Allergy - Drug Targets, 2007
- Cardiac Hypertrophy: Molecular and Cellular EventsRevista Española de Cardiología (English Edition), 2006
- Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulationCardiovascular Research, 2003